How Will $5 Rapid COVID Test Affect the Overall Stock Market?

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Abbott Laboratories (NYSE:ABT) received approval from the FDA for its rapid antigen test. The test which allegedly can detect whether a patient has COVID-19 in under 15 minutes.

According to healthcare professionals the “$5 rapid test” could be the game changer in testing protocols for the virus.

As there is an increasing perception that the Coronavirus is less of a threat with new testing methods like this one and possible vaccinations developing… how will the market react to short-term COVID headlines and where will the broader markets trend towards?

Well, Abbott’s stock was up 8% on the back of the news as of writing this and transports such as airlines and cruise-liners were starting to catch a bid.

Watch the full interview to see which stocks Lance Ippolito is trading to make money today…

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.